



Kavitha Ramchandran

Clinical Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Division of Oncology**

875 Blake Wilbur Dr Rm 2231

MC 6574

Stanford, CA 94305

Tel (650) 724-6668 **Fax** (650) 725-5849

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Ashnee Gounden - Research Administrative Coordinator

Email ashnee@stanford.edu

Bio

BIO

Kavitha Ramchandran MD, graduated with an undergraduate degree in Human Biology from Stanford University, did medical school and residency training in medicine at University of California, San Francisco and completed her fellowship in Medical Oncology and Palliative Medicine at Northwestern University, Chicago. She joined faculty at Stanford University in 2010. Currently she is a Clinical Associate Professor of Medicine in the Division of Oncology. She serves as the Medical Director of Cancer Care Services for the Stanford Cancer Center across the enterprise, and is the inaugural Chief of Mentoring and Career Development for the Division of Oncology.

Dr. Ramchandran is recognized for her contributions as a leader in the research of thoracic malignancies with a specific focus in thymic epithelial tumors. She serves as a principal investigator and sub-investigator on several research trials from early phase to phase II and phase III studies. The goal of these trials is developing novel approaches and identifying new targets for the treatment of both thoracic malignancies as well as rare tumors such as thymic epithelial tumors including thymoma and thymic cancers.

Dr. Ramchandran also has research focuses on developing care delivery models that incorporate values (patients, family members, and clinicians), as well as novel means of palliative care education. She does research on online education and in patient reported outcomes (PROs). She also is part of an active thoracic oncology trials group recruiting patients for clinical trials using novel therapeutics.

Dr. Ramchandran is recognized for her contributions as a leader in the integration of palliative and oncology care. Dr. Ramchandran is one of a small number of dual trained faculty who are working to build synergies between the fields of oncology and palliative medicine in the areas of supportive care research, and novel models of care. In her care of patients Dr. Ramchandran values a deep relationship with the families she cares for. She provides care that is aligned with the patient and family's personal values with the goal of the best quality of life and longevity possible.

CLINICAL FOCUS

- Cancer > Thoracic Oncology

- Palliative Medicine
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Medical Director, Cancer Care Services, Stanford Cancer Center, (2019- present)

HONORS AND AWARDS

- Honoree, Clinical Effectiveness Leadership Training- CELT (2014)
- Nominee, Medical Residency Teaching Award (2012)
- Honoree, AACR/ASCO: Methods in Clinical Cancer Research (2009)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Associate Chief of Mentoring and Career Development, Division of Oncology, School of Medicine (2021 - present)
- Geriatric Oncology Panel, National Comprehensive Cancer Network (2021 - present)
- Fellow, Center for Global Health, Stanford University (2020 - present)
- Palliative Care Panel, National Comprehensive Cancer Network (2020 - present)
- Medical Director, Cancer Care Services, Stanford Cancer Center (2019 - present)
- Faculty, Global Oncology- GO (2015 - present)
- Palliative Care Best Practices Committee, National Comprehensive Cancer Network (2014 - present)
- Patient and Survivor Care Committee, American Society of Clinical Oncology (2014 - present)
- Faculty, Global Resource to Advance Cancer Education (2012 - present)
- Board member, Cancer Awareness, Research and Education, San Francisco General Hospital (2002 - present)

PROFESSIONAL EDUCATION

- Residency: UCSF Dept of Internal Medicine (2007) CA
- Fellowship: Northwestern University Hematology and Oncology Fellowship (2009) IL
- Board Certification: Hospice and Palliative Medicine, American Board of Internal Medicine (2012)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2010)
- Medical Education: University of California at San Francisco School of Medicine (2004) CA
- Board Certification, Oncology , Oncology (2009)

COMMUNITY AND INTERNATIONAL WORK

- Global Oncology, TBD

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research focuses on innovative models of care delivery to understand how to integrate primary and specialist palliative care. We also do work in palliative care education and how to scale our education to be impactful and sustainable. We are evaluating online models.

In cancer care I do research on novel therapeutics in thoracic malignancies including immunotherapy, new targeted agents, and new sequencing of approved drugs.

CLINICAL TRIALS

- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1/2 Study to Evaluate MEDI4736, Not Recruiting
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- A Prospective Trial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR], Not Recruiting
- A Study of Onartuzumab (MetMab) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer, Not Recruiting
- A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer, Not Recruiting
- Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation, Not Recruiting
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026), Not Recruiting
- Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor, Not Recruiting
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial), Not Recruiting
- Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer, Not Recruiting
- Erlotinib and Mometinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC), Not Recruiting
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial), Not Recruiting
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia, Not Recruiting
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial), Not Recruiting
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib, Not Recruiting
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer, Not Recruiting
- MAGE A10^Δ for Advanced NSCLC, Not Recruiting
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor, Not Recruiting
- Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer, Not Recruiting
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer, Not Recruiting
- Phase 2 Etrirotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer, Not Recruiting

- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer, Not Recruiting
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination, Not Recruiting
- Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010], Not Recruiting
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients, Not Recruiting
- TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy, Not Recruiting

PROJECTS

- Model of Care: Integration of palliative care into cancer care using a human centered design approach

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Health Services Research (Masters Program)
- Medicine (Masters Program)
- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy** *JTO CLINICAL AND RESEARCH REPORTS*
V. Aredo, J., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W. 2025; 6 (12)
- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.** *JTO clinical and research reports*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J. 2025; 6 (12): 100914
- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.** *JTO clinical and research reports*
Aredo, J. V., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W. 2025; 6 (12): 100913
- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System- Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes** *JTO CLINICAL AND RESEARCH REPORTS*
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J. 2025; 6 (12)
- **BRIDGING DIVISIONS: ASSESSING COHORT-BASED PEER MENTORSHIP FOR EARLY-CAREER FACULTY IN ACADEMIC MEDICINE**
Ye, G., Anand, S., Artandi, M., Collins, W., Go, M., Nguyen, L., Wang, P., Weng, W., Ramchandran, K., Singh, U. SPRINGER.2025: S490
- **Nativity status and non-small cell lung cancer outcomes**
Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Myall, N. J., Roy, M., Wakelee, H. A. AMER ASSOC CANCER RESEARCH.2025: B144
- **Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Sun, F., Banwait, M. K., Singhal, S., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L., Ullah, A. T., Guo, E. W., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, et al

2025; 208: 108747

- **Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response.** *JTO clinical and research reports*
van 't Erve, I., Blanchard, I., Pagtama, J. Y., Holmes Tisch, A. J., Alizadeh, A. A., Ramchandran, K., Wakelee, H. A., Padda, S. K., Diehn, M., Neal, J. W.
2025; 6 (9): 100877
- **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy.** *JACC. CardioOncology*
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al
2025
- **Smoking Trends in KRAS-Mutated Non-Small Cell Lung Cancer at a Tertiary Referral Center**
Aredo, J., Neal, J. W., Ramchandran, K. J., Das, M. S., Myall, N. J., Wakelee, H. A.
ELSEVIER SCIENCE INC.2025
- **Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.** *Cancer discovery*
Moding, E. J., Shahrokh Esfahani, M., Jin, C., Hui, A. B., Nabet, B. Y., Liu, Y., Chabon, J. J., Binkley, M. S., Kurtz, D. M., Hamilton, E. G., Chaudhuri, A. A., Liu, C. L., Li, et al
2025: OF1-OF21
- **QIM25-226: What Patients Anticipate About Working Out with Cancer: Qualitative Survey Results.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Sibley, A., Lauwers, S., Asuncion, K., Liang, J., Giarrusso, J., Bernardez, D., Holdsworth, L., Ramchandran, K.
2025; 23 (3.5)
- **Comparison of 1-year mortality predictions from vendor-supplied versus academic model for cancer patients.** *PeerJ*
Gensheimer, M. F., Lu, J., Ramchandran, K.
2025; 13: e18958
- **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC** *JTO CLINICAL AND RESEARCH REPORTS*
Aredo, J., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12)
- **Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.** *JTO clinical and research reports*
Aredo, J. V., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A. B., Salahudeen, A., Kwong, B., Berry, G. J., Guo, H. H., Cunanan, K., Vali, S., Pancirer, et al
2024; 5 (12): 100741
- **Automated patient selection and care coaches to increase advance care planning for cancer patients.** *Journal of the National Cancer Institute*
Gensheimer, M. F., Teuteberg, W., Patel, M. I., Gupta, D., Noroozi, M., Ling, X., Fardeen, T., Seevaratnam, B., Lu, Y., Alves, N., Rogers, B., Asuncion, M. K., Denofrio, et al
2024
- **A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.** *International journal of radiation oncology, biology, physics*
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. v., Pratapneni, A., Le-Budka, M. L., Wong, S., Brown, E., Barnick, K., Wakelee, H. A., Das, et al
2024
- **Using Patient-Related Outcomes Data to Inform About a Novel Exercise Program in Oncology Patients.** *Journal of cancer education : the official journal of the American Association for Cancer Education*
Sibley, A., Schapira, L., Ramchandran, K.
2024
- **Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Presley, C. J., Dalal, N., Davenport, A. P., Gounden, A., Ramchandran, K., Tonorezos, E.
2024; 44 (3): e433298

- **Personalized Accelerated ChEموRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.** *Clinical lung cancer*
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., Ramchandran, K., Myall, N. J., Pham, D., Xing, L., Yang, Y., Kovalchuk, N., Yuan, et al
2023
- **Lessons Learned from a Multi-Site, Team-Based Serious Illness Care Program Implementation at an Academic Medical Center.** *Journal of palliative medicine*
Seevaratnam, B., Wang, S., Fong, R., Hui, F., Callahan, A., Chobot, S., Gensheimer, M. F., Li, R. C., Nguyen, D., Ramchandran, K., Shah, N. H., Shieh, L., Zeng, et al
2023
- **Study of Patient and Physician Attitudes Toward Automated Prognostic Models for Patients With Metastatic Cancer.** *JCO clinical cancer informatics*
Hildebrand, R. D., Chang, D. T., Ewongwoo, A. N., Ramchandran, K. J., Gensheimer, M. F.
2023; 7: e2300023
- **Patient-reported distress at a cancer center during the COVID-19 pandemic.** *Scientific reports*
Shah, M. P., Rosenthal, S. W., Roy, M., Khaki, A. R., Hernandez-Boussard, T., Ramchandran, K.
2023; 13 (1): 9581
- **Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., Neal, J. W., Wakelee, H. A., Ramchandran, K., Gensheimer, M. F., Diehn, M., Chin, A. L., Loo, et al
2023
- **Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.** *Frontiers in oncology*
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., Soltys, S. G., Pollom, E. L., Chin, A., Vitzthum, L., Wakelee, H. A., Padda, S. K., Ramchandran, et al
2023; 13: 1139940
- **Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Stetson, P. D., McCleary, N. J., Osterman, T., Ramchandran, K., Tevaarwerk, A., Wong, T., Sugalski, J. M., Akerley, W., Mercurio, A., Yamzon, J., Stillman, R. C., Gabriel, P. E., Heinrichs, et al
2022; 20 (13)
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128
- **Plasma Exchange for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Therapy: Implications for Clinical Care and Clinical Trial Design**
Giri, V. K., Yunce, M., Muppidi, S., Ramchandran, K. J., Katsumoto, T. R., Martin-Kool, B. A.
AMER SOC HEMATOLOGY.2022: 2835-2836
- **Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer**
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lin, J. Y., Lu, J. T., Li, G., Hayden, M., Myall, N., Soltys, et al
ELSEVIER SCIENCE INC.2022: E54-E55
- **Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.** *Journal of neuro-oncology*
Hui, C., Qu, V., Wang, J. Y., von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lu, J. T., Li, G., Hayden-Gephart, M., Wakelee, H., Neal, J., Ramchandran, et al
2022
- **Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.** *Cancer investigation*
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., Lythgoe, M. P., Khaki, A. R.
2022: 1-6

- **Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening.**
Gupta, D., Savadamuthu, V., Qin, F., Roy, M., Herring, J., Robinson, A., Terrell, C., Neal, J. W., Lahijani, S., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2022: 278
- **Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., Greenlee, H., Leblanc, T., Lee, R. T., Lopez, A. M., Loprinzi, C., Lyman, G. H., MacLeod, et al
2022: JCO2201357
- **Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.** *Clinical lung cancer*
Waliyany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., Li, C., Pagtama, J., Tisch, A. H., Neal, J. W.
2022
- **Patient-reported distress at a cancer center during the COVID-19 pandemic.**
Shah, M. P., Rosenthal, S., Roy, M., Khaki, A., Hernandez-Boussard, T., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18644
- **Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?** *Immunotherapy advances*
Katsumoto, T. R., Wilson, K. L., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., Martin, B. A., Yunce, M., Muppidi, S.
2022; 2 (1): Itac012
- **Considerations in the reliability and fairness audits of predictive models for advance care planning** *Frontiers in Digital Health*
Lu, J., Sattler, A., Wang, S., Khaki, A. R., Callahan, A., Fleming, S., Fong, R., Ehler, B., Li, R., Shieh, L., Ramchandran, K., Gensheimer, M., Chobot, et al
2022: 943768
- **Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.** *Clinical lung cancer*
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., Padda, S. K., Ramchandran, K., Chen, T. T., Sequist, L. V., Piotrowska, Z., Wakelee, H. A.
2021
- **Palliative Care Always: Hepatology-Virtual Primary Palliative Care Training for Hepatologists.** *Hepatology communications*
DeNofrio, J. C., Verma, M., Kosinski, A. S., Navarro, V., Taddei, T. H., Volk, M. L., Bakitas, M., Ramchandran, K.
2021
- **Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.** *Clinical lung cancer*
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2021
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Patients' perception of meaning of life and needed support before and after cancer treatment initiation**
Roy, M., Rosenthal, S., Shah, M., Khaki, A., Hernandez-Boussard, T., Ramchandran, K.
SPRINGER.2021: S156-S157
- **Association of telemedicine use with disparities in cancer distress screening for patients with limited English proficiency**
Roy, M., Fardeen, T., Cabot, A., Bruzzone, B., Savadamuthu, V., Kasprick, D., Cheung, L., Teske, E., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Association of treatment type with patient-reported quality of life in cancer distress screening**
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A., Bozkurt, S., Seto, T., Blayney, D. W., Hernandez-Boussard, T., Ramchandran, K.
LIPPINCOTT WILLIAMS & WILKINS.2021

- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al
2021; 5 (1): 91
- **Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients**
Tan, I., Choi, J., Cunanan, K., Fronk, J., Zhang, T., Mannis, G. N., Ramchandran, K.
CIG MEDIA GROUP, LP.2021: S279-S280
- **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Waliyany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021
- **EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.** *Clinical lung cancer*
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., Neal, J. W.
2021
- **Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.**
Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., Yoo, C., Kurtz, D. M., Owen, S., Backhus, L. M., Berry, M. F., Shrager, J. B., Ramchandran, et al
AMER ASSOC CANCER RESEARCH.2021
- **Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.**
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z., Das, M., Ramchandran, K. J., Padda, S. K., Neal, et al
AMER ASSOC CANCER RESEARCH.2021
- **How could we forget?** *The Lancet. Respiratory medicine*
Ramchandran, K.
2021
- **End-of-Life Practice Patterns in Head and Neck Cancer.** *The Laryngoscope*
Vukkadala, N., Fardeen, T., Ramchandran, K., Divi, V.
2021
- **Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.** *Journal of neuro-oncology*
Zhang, M. n., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., Neal, J. W., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Chang, S. D., Lim, M. n., Hayden Gephart, et al
2021
- **NCCN Guidelines Insights: Palliative Care, Version 2.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Dans, M., Kutner, J. S., Agarwal, R., Baker, J. N., Bauman, J. R., Beck, A. C., Campbell, T. C., Carey, E. C., Case, A. A., Dalal, S., Doberman, D. J., Epstein, A. S., Fecher, et al
2021; 19 (7): 780-788
- **Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.** *JCO oncology practice*
Neal, J. W., Roy, M. n., Bugos, K. n., Sharp, C. n., Galatin, P. S., Falconer, P. n., Rosenthal, E. L., Blayney, D. W., Modaressi, S. n., Robinson, A. n., Ramchandran, K. n.
2021: OP2000473
- **Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Hellyer, J. A., Aredo, J. V., Das, M. n., Ramchandran, K. n., Padda, S. K., Neal, J. W., Wakelee, H. A.
2021
- **End-of-Life Cost Trajectories in Cancer Patients Treated by Medicare versus the Veterans Health Administration.** *Journal of the American Geriatrics Society*

Gidwani, R., Asch, S. M., Needleman, J., Faricy-Anderson, K., Boothroyd, D. B., Illarmo, S., Lorenz, K. A., Patel, M. I., Hsin, G., Ramchandran, K., Wagner, T. H.

2020

● **DEVELOPMENT, FEASIBILITY AND ACCEPTABILITY OF AN ONLINE COURSE TO TEACH PRIMARY PALLIATIVE CARE SKILLS TO HEPATOLOGY PROVIDERS.**

Verma, M., Denofrio, J., Ramchandran, K., Taddei, T. H., Volk, M., Navarro, V. J.

WILEY.2020: 1156–57

● **A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer**

Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., Steen, C. B., Chaudhuri, A. A., Liu, C., Hui, A. B., Stehr, H., Gojenola, L., Jin, et al

AMER ASSOC CANCER RESEARCH.2020

● **The role of palliative care in the management of patients with lung cancer** *LUNG CANCER MANAGEMENT*

Tan, I., Ramchandran, K.

2020

● **Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.**

Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E., Blayney, D. W., Modaresi, S., Robinson, A., Ramchandran, K.

AMER SOC CLINICAL ONCOLOGY.2020

● **A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.**

Moding, E. J., Esfahani, M., Nabet, B., Liu, Y., Chabon, J. J., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, Z. X., Das, M., Ramchandran, et al

AMER SOC CLINICAL ONCOLOGY.2020

● **KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.**

Binkley, M. S., Jeon, Y., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., Yoo, C., Kurtz, D., Owen, S., Backhus, L., Berry, M. F., Shrager, J. B., Ramchandran, et al

AMER SOC CLINICAL ONCOLOGY.2020

● **Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.** *Nature cancer*

Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., Jones, C. D., He, J., Qiao, et al

2020; 1 (2): 176-183

● **Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.** *Cell*

Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H. n., Steen, C. B., Chaudhuri, A. A., Liu, C. L., Hui, A. B., Almanza, D. n., Stehr, H. n., Gojenola, et al

2020

● **KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.** *Cancer discovery*

Binkley, M. S., Jeon, Y. J., Nesselbush, M. n., Moding, E. J., Nabet, B. Y., Almanza, D. n., Kunder, C. n., Stehr, H. n., Yoo, C. H., Rhee, S. n., Xiang, M. n., Chabon, J. J., Hamilton, et al

2020

● **Symptom relief and palliative care in gynecologic oncology.** *Current opinion in obstetrics & gynecology*

Roy, M., Ramchandran, K.

2019

● **Palliative care clinicians and online education in India: a survey** *BMJ SUPPORTIVE & PALLIATIVE CARE*

Kiss-Lane, T., Spruijt, O., Day, T., Lam, V., Ramchandran, K. J., Chan, S., Hsin, G., Vallath, N., Bhatnagar, S., Rajagopal, M. R., Lorenz, K. A.

2019; 9 (4)

● **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**

Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al

AMER SOC CLINICAL ONCOLOGY.2019

● **Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial.** *Journal of palliative medicine*

- Verma, M., Kosinski, A. S., Volk, M. L., Taddei, T., Ramchandran, K., Bakitas, M., Green, K., Green, L., Navarro, V.
2019; 22 (S1): 34–43
- **Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Gensheimer, M. F., Henry, A., Wood, D. J., Hastie, T. J., Aggarwal, S., Dudley, S. A., Pradhan, P., Banerjee, I., Cho, E., Ramchandran, K., Pollom, E., Koong, A. C., Rubin, et al
2019; 111 (6): 568–74
 - **ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.**
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., He, J., Qiao, Y., Heymach, J., Tsao, A. S., Liao, Z. X., Gomez, D., Ramchandran, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.**
Chaft, J. E., Costa, D., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., Ramchandran, K., Rangachari, D., Huberman, M., Piotrowska, Z., Kris, M. G., Azzoli, C. G., Sequist, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Stehr, H. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Diehn, M. n., Wakelee, H. A.
2019; 134: 42–45
 - **Health System and Beneficiary Costs Associated With Intensive End-of-Life Medical Services.** *JAMA network open*
Gidwani-Marszowski, R. n., Asch, S. M., Mor, V. n., Wagner, T. H., Faricy-Anderson, K. n., Illarmo, S. n., Hsin, G. n., Patel, M. I., Ramchandran, K. n., Lorenz, K. A., Needleman, J. n.
2019; 2 (9): e1912161
 - **Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M. n., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M. n., Ramchandran, K. J., Neal, J. W., Wakelee, H. A., Loehrer, P. J.
2019; 137: 71–75
 - **Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jeong, Y. n., Hellyer, J. A., Stehr, H. n., Hoang, N. T., Niu, X. n., Das, M. n., Padda, S. K., Ramchandran, K. n., Neal, J. W., Wakelee, H. A., Diehn, M. n.
2019
 - **Feasibility of a massive online open course to teach skills in primary palliative care for a global audience.**
Kerker, A., DeNofrio, J., Tribett, E., Ramchandran, K.
AMER SOC CLINICAL ONCOLOGY.2018
 - **Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data.** *Journal of the National Cancer Institute*
Gensheimer, M. F., Henry, A. S., Wood, D. J., Hastie, T. J., Aggarwal, S., Dudley, S. A., Pradhan, P., Banerjee, I., Cho, E., Ramchandran, K., Pollom, E., Koong, A. C., Rubin, et al
2018
 - **Palliative care clinicians and online education in India: a survey.** *BMJ supportive & palliative care*
Kiss-Lane, T., Spruijt, O., Day, T., Lam, V., Ramchandran, K. J., Chan, S., Hsin, G., Vallath, N., Bhatnagar, S., Rajagopal, M. R., Lorenz, K. A.
2018
 - **Oncologists' Views on Using Value to Guide Cancer Treatment Decisions** *VALUE IN HEALTH*
Gidwani-Marszowski, R., Nevedal, A. L., Blayney, D. W., Patel, M., Kelly, P., Timko, C., Ramchandran, K., Murrell, S. S., Asch, S. M.
2018; 21 (8): 931–37
 - **Quality Of End-Of-Life Care Is Higher In The VA Compared To Care Paid For By Traditional Medicare** *HEALTH AFFAIRS*

- Gidwani-Marszowski, R., Needleman, J., Mor, V., Faricy-Anderson, K., Boothroyd, D. B., Hsin, G., Wagner, T. H., Lorenz, K. A., Patel, M. I., Joyce, V. R., Murrell, S. S., Ramchandran, K., Asch, et al
2018; 37 (1): 95–103
- **The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives** *JOURNAL OF PALLIATIVE MEDICINE*
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., Kelly, P. A., Asch, S. M.
2017; 20 (4): 395-403
 - **The Appropriate Provision of Primary Versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives.** *Journal of palliative medicine*
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., Kelly, P. A., Asch, S. M.
2016
 - **The Current State of Palliative Care for Patients Cared for at Leading US Cancer Centers: The 2015 NCCN Palliative Care Survey.** *Journal of the National Comprehensive Cancer Network*
Calton, B. A., Alvarez-Perez, A., Portman, D. G., Ramchandran, K. J., Sugalski, J., Rabow, M. W.
2016; 14 (7): 859-866
 - **Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer.** *Current treatment options in oncology*
Chandrasekar, D., Tribett, E., Ramchandran, K.
2016; 17 (5): 23-?
 - **Integrating Palliative Care Into Oncology: A Way Forward** *CANCER CONTROL*
Ramchandran, K., Tribett, E., Dietrich, B., Von Roenn, J.
2015; 22 (4): 386-395
 - **Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.** *Annals of oncology*
Lee, R. T., Ramchandran, K., Sanft, T., Von Roenn, J.
2015; 26 (9): 1838-1845
 - **Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.** *Clinical lung cancer*
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., Neal, J. W., Wakelee, H. A.
2014; 15 (3): 202-206
 - **A predictive model to identify hospitalized cancer patients at risk for 30-day mortality based on admission criteria via the electronic medical record.** *Cancer*
Ramchandran, K. J., Shega, J. W., von Roenn, J., Schumacher, M., Szmuiłowicz, E., Rademaker, A., Weitner, B. B., Loftus, P. D., Chu, I. M., Weitzman, S.
2013; 119 (11): 2074-2080
 - **Palliative Care Always** *ONCOLOGY-NEW YORK*
Ramchandran, K., Von Roenn, J. H.
2013; 27 (1): 13-?
 - **Emerging Concepts in the Pathology and Molecular Biology of Advanced Non-Small Cell Lung Cancer** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Kulesza, P., Ramchandran, K., Patel, J. D.
2011; 136 (2): 228-238
 - **Phantom Limb Pain #212** *JOURNAL OF PALLIATIVE MEDICINE*
Ramchandran, K., Hauser, J.
2010; 13 (10): 1285-1286
 - **Sex Differences in Susceptibility to Carcinogens** *SEMINARS IN ONCOLOGY*
Ramchandran, K., Patel, J. D.
2009; 36 (6): 516-523
 - **My Friend, My Patient** *JOURNAL OF PALLIATIVE MEDICINE*

Ramchandran, K.
2009; 12 (1): 95-96